[ad_1]
On day 9, the US Food and Drug Administration (FDA) granted an emergency license (EUA) for adult and pediatric patients with a new mild to moderate coronavirus infection (COVID19) for the antibody drug monoclonal bamuranibimab from Eli Lily from the USA Announced. Initial data on the drug suggests that it helps avoid hospitalization for corona-infected people.
Eli Lily’s stock rose 4.5% at a time during overtime trading the same day. Target adults include those over the age of 65.
The decision gives doctors the option of dealing with high-risk patients before they become so severe that they are forced to be hospitalized.Other treatments that authorities have approved so far, such as Gilliad Sciences’ antiviral drug Remdecibir, are for critically ill patients in Corona.
In the future, the most difficult supply test awaits. Eli Lily said in a statement yesterday that bamuranibimab should be administered “if the corona test is positive, as soon as possible, within 10 days after the onset of symptoms.” The company is a pharmaceutical wholesaler.It will begin shipping to the American Resource Bargain immediately and will be supplied from there as directed by the US government Medical institutions may charge the public for intravenous administration, but the drug itself is not at the public’s expense.
Antibody drugs can be one of the important tools that doctors can use in corona treatment. Anthony Fouch, director of the National Institute of Allergic Infectious Diseases (NIAID), also mentioned that antibody drugs will be a bridge to the practical application of vaccines.
Antibody drugs are also being studied as a short-term treatment that can be given to residents of nursing homes and staff who may have been exposed to the virus to prevent infection of residents.
Eli Lily is a Canadian biotechnology companyIn October, the US applied to the FDA for Bamuranibimab, which was jointly developed with Abselera Biologics.
Eli Lily applies to FDA for emergency use permit for new corona antibody therapy
According to preliminary results from a clinical trial published by Eli Lily in September, the percentage of symptomatic patients requiring hospitalization or emergency treatment was lower than that of the placebo group (fake). The value of the virus level in the patient decreased by half of the three doses. The results of the test were published in the American medical journal New England Journal of Medicine (NEJM).
The US government agreed to pay $ 375 million for 300,000 vials on the US condition. It will be available for the first two months after the US acquisition, but the US government has the option to purchase an additional 650,000 vials for up to $ 812.5 million by June of next year.
Eli Lily agrees with the US government to supply a new corona antibody drug – $ 375 million
According to David Rix, CEO, the company has a production partnership with Amgen and plans to find more partners.
Original title:Eli Lilly Covid Antibody Drug Gets FDA Emergency Clearance (2)
(Abstract)
(I will update it by adding a description about the supply in the fourth paragraph)
